Mesoblast Statistics
Total Valuation
Mesoblast has a market cap or net worth of $1.88 billion. The enterprise value is $1.84 billion.
Important Dates
The last earnings date was Thursday, August 28, 2025, after market close.
| Earnings Date | Aug 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Mesoblast has 1.28 billion shares outstanding. The number of shares has increased by 22.41% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.28B |
| Shares Change (YoY) | +22.41% |
| Shares Change (QoQ) | +11.47% |
| Owned by Insiders (%) | 37.27% |
| Owned by Institutions (%) | 25.67% |
| Float | 774.10M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 109.13 |
| Forward PS | 33.79 |
| PB Ratio | 3.14 |
| P/TBV Ratio | 73.27 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 107.17 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.99, with a Debt / Equity ratio of 0.21.
| Current Ratio | 1.99 |
| Quick Ratio | 1.72 |
| Debt / Equity | 0.21 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.87 |
Financial Efficiency
Return on equity (ROE) is -18.95% and return on invested capital (ROIC) is -5.89%.
| Return on Equity (ROE) | -18.95% |
| Return on Assets (ROA) | -5.37% |
| Return on Invested Capital (ROIC) | -5.89% |
| Return on Capital Employed (ROCE) | -9.16% |
| Revenue Per Employee | $212,321 |
| Profits Per Employee | -$1.26M |
| Employee Count | 81 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Mesoblast has paid $330,000 in taxes.
| Income Tax | 330,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +139.81% in the last 52 weeks. The beta is 1.17, so Mesoblast's price volatility has been higher than the market average.
| Beta (5Y) | 1.17 |
| 52-Week Price Change | +139.81% |
| 50-Day Moving Average | 14.41 |
| 200-Day Moving Average | 13.87 |
| Relative Strength Index (RSI) | 50.33 |
| Average Volume (20 Days) | 230,729 |
Short Selling Information
| Short Interest | 2.42M |
| Short Previous Month | 2.38M |
| Short % of Shares Out | 2.59% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 15.58 |
Income Statement
In the last 12 months, Mesoblast had revenue of $17.20 million and -$102.14 million in losses. Loss per share was -$0.08.
| Revenue | 17.20M |
| Gross Profit | -22.74M |
| Operating Income | -62.44M |
| Pretax Income | -73.25M |
| Net Income | -102.14M |
| EBITDA | -58.18M |
| EBIT | -62.44M |
| Loss Per Share | -$0.08 |
Full Income StatementBalance Sheet
The company has $161.55 million in cash and $128.16 million in debt, giving a net cash position of $33.39 million or $0.03 per share.
| Cash & Cash Equivalents | 161.55M |
| Total Debt | 128.16M |
| Net Cash | 33.39M |
| Net Cash Per Share | $0.03 |
| Equity (Book Value) | 597.44M |
| Book Value Per Share | 0.47 |
| Working Capital | 101.72M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$49.95 million and capital expenditures -$680,000, giving a free cash flow of -$50.63 million.
| Operating Cash Flow | -49.95M |
| Capital Expenditures | -680,000 |
| Free Cash Flow | -50.63M |
| FCF Per Share | -$0.04 |
Full Cash Flow StatementMargins
| Gross Margin | -132.22% |
| Operating Margin | -363.08% |
| Pretax Margin | -592.00% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Mesoblast does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -22.41% |
| Shareholder Yield | -22.41% |
| Earnings Yield | -5.44% |
| FCF Yield | -2.70% |
Analyst Forecast
The average price target for Mesoblast is $18.00, which is 21.46% higher than the current price. The consensus rating is "Buy".
| Price Target | $18.00 |
| Price Target Difference | 21.46% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 115.81% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 10, 2024. It was a reverse split with a ratio of 1:2.
| Last Split Date | Jan 10, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:2 |
Scores
Mesoblast has an Altman Z-Score of 2.45 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.45 |
| Piotroski F-Score | 5 |
